The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Cervical Cancer (v2024.0)
: Recent publications underscore the need for updated recommendations addressing less radical surgery for
Gespeichert in:
| Veröffentlicht in: | Journal of clinical medicine 2024-08, Vol.13 (15), p.4351 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 15 |
| container_start_page | 4351 |
| container_title | Journal of clinical medicine |
| container_volume | 13 |
| creator | Sznurkowski, Jacek J Bodnar, Lubomir Szylberg, Łukasz Zołciak-Siwinska, Agnieszka Dańska-Bidzińska, Anna Klasa-Mazurkiewicz, Dagmara Rychlik, Agnieszka Kowalik, Artur Streb, Joanna Bidziński, Mariusz Sawicki, Włodzimierz |
| description | : Recent publications underscore the need for updated recommendations addressing less radical surgery for |
| doi_str_mv | 10.3390/jcm13154351 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_3091285474</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A804511904</galeid><sourcerecordid>A804511904</sourcerecordid><originalsourceid>FETCH-LOGICAL-c309t-fda6c4d8fd2576831a5d6fdf251e684bd9d382d18ac1b5032f2133d4c550e3283</originalsourceid><addsrcrecordid>eNptkc1rGzEQxUVpaEKSU-9F0ItLsKPPXe3RuIlbCCRQ97zI0siR2ZVSaTfg_z67sVPcktFhBvF7bwYeQp8pmXFekeutaSmnUnBJP6AzRspySrjiH4_mU3SZ85YMpZRgtPyETnlFmSgYOUPd6hHwQ2x8fsS_ovHQ7XB0eLkLYGITN97oBt-H13mHl7230PgAGbuYcDdov3u9CTH7jHWweJVAdy2EbjRZQHp-1S90MJDw5JkRJmbk2wU6cbrJcHno5-j37c1q8WN6d7_8uZjfTQ0nVTd1VhdGWOUsk2WhONXSFs46JikUSqxtZblilipt6FoSzhyjnFthpCTAmeLnaLL3fUrxTw-5q1ufDTSNDhD7XA9bKFNSlGJAv_6HbmOfwnDdSJGKlaw6oja6gdoHF7ukzWhazxURktKKjNTsHWp4FlpvYgDnh_9_BFd7gUkx5wSufkq-1WlXU1KPMddHMQ_0l8Op_boF-5d9C5W_AKqUnqc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3090927294</pqid></control><display><type>article</type><title>The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Cervical Cancer (v2024.0)</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Sznurkowski, Jacek J ; Bodnar, Lubomir ; Szylberg, Łukasz ; Zołciak-Siwinska, Agnieszka ; Dańska-Bidzińska, Anna ; Klasa-Mazurkiewicz, Dagmara ; Rychlik, Agnieszka ; Kowalik, Artur ; Streb, Joanna ; Bidziński, Mariusz ; Sawicki, Włodzimierz</creator><creatorcontrib>Sznurkowski, Jacek J ; Bodnar, Lubomir ; Szylberg, Łukasz ; Zołciak-Siwinska, Agnieszka ; Dańska-Bidzińska, Anna ; Klasa-Mazurkiewicz, Dagmara ; Rychlik, Agnieszka ; Kowalik, Artur ; Streb, Joanna ; Bidziński, Mariusz ; Sawicki, Włodzimierz</creatorcontrib><description>: Recent publications underscore the need for updated recommendations addressing less radical surgery for <2 cm tumors, induction chemotherapy, or immunotherapy for locally advanced stages of cervical cancer, as well as for the systemic therapy for recurrent or metastatic cervical cancer.
: To summarize the current evidence for the diagnosis, treatment, and follow-up of cervical cancer and provide evidence-based clinical practice recommendations.
: Developed according to AGREE II standards, the guidelines classify scientific evidence based on the Agency for Health Technology Assessment and Tariff System criteria. Recommendations are graded by evidence strength and consensus level from the development group.
: (1) Early-Stage Cancer: Stromal invasion and lymphovascular space involvement (LVSI) from pretreatment biopsy identify candidates for surgery, particularly for simple hysterectomy. (2) Surgical Approach: Minimally invasive surgery is not recommended, except for T1A, LVSI-negative tumors, due to a reduction in life expectancy. (3) Locally Advanced Cancer: concurrent chemoradiation (CCRT) followed by brachytherapy (BRT) is the cornerstone treatment. Low-risk patients (fewer than two metastatic nodes or FIGO IB2-II) may consider induction chemotherapy (ICT) followed by CCRT and BRT after 7 days. High-risk patients (two or more metastatic nodes or FIGO IIIA, IIIB, and IVA) benefit from pembrolizumab with CCRT and maintenance therapy. (4) Metastatic, Persistent, and Recurrent Cancer: A PD-L1 status from pretreatment biopsy identifies candidates for Pembrolizumab with available systemic treatment, while triplet therapy (Atezolizumab/Bevacizumab/chemotherapy) becomes a PD-L1-independent option.
: These evidence-based guidelines aim to improve clinical outcomes through precise treatment strategies based on individual risk factors, predictors, and disease stages.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm13154351</identifier><identifier>PMID: 39124620</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Cancer ; Cancer therapies ; Care and treatment ; Cellular biology ; Cervical cancer ; Classification ; Clinical trials ; Confidence intervals ; Cost control ; Diagnosis ; Evaluation ; Evidence-based medicine ; Exhumation ; Gynecology ; Health technology assessment ; Human papillomavirus ; Immunotherapy ; Infections ; Medical screening ; Minimally invasive surgery ; Oncology ; Patients ; Practice guidelines (Medicine) ; Radiotherapy ; Risk factors ; Womens health</subject><ispartof>Journal of clinical medicine, 2024-08, Vol.13 (15), p.4351</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c309t-fda6c4d8fd2576831a5d6fdf251e684bd9d382d18ac1b5032f2133d4c550e3283</cites><orcidid>0000-0003-1349-5906 ; 0000-0003-4767-6369 ; 0000-0001-9218-0245 ; 0000-0002-3718-999X ; 0000-0003-0122-9504</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39124620$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sznurkowski, Jacek J</creatorcontrib><creatorcontrib>Bodnar, Lubomir</creatorcontrib><creatorcontrib>Szylberg, Łukasz</creatorcontrib><creatorcontrib>Zołciak-Siwinska, Agnieszka</creatorcontrib><creatorcontrib>Dańska-Bidzińska, Anna</creatorcontrib><creatorcontrib>Klasa-Mazurkiewicz, Dagmara</creatorcontrib><creatorcontrib>Rychlik, Agnieszka</creatorcontrib><creatorcontrib>Kowalik, Artur</creatorcontrib><creatorcontrib>Streb, Joanna</creatorcontrib><creatorcontrib>Bidziński, Mariusz</creatorcontrib><creatorcontrib>Sawicki, Włodzimierz</creatorcontrib><title>The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Cervical Cancer (v2024.0)</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>: Recent publications underscore the need for updated recommendations addressing less radical surgery for <2 cm tumors, induction chemotherapy, or immunotherapy for locally advanced stages of cervical cancer, as well as for the systemic therapy for recurrent or metastatic cervical cancer.
: To summarize the current evidence for the diagnosis, treatment, and follow-up of cervical cancer and provide evidence-based clinical practice recommendations.
: Developed according to AGREE II standards, the guidelines classify scientific evidence based on the Agency for Health Technology Assessment and Tariff System criteria. Recommendations are graded by evidence strength and consensus level from the development group.
: (1) Early-Stage Cancer: Stromal invasion and lymphovascular space involvement (LVSI) from pretreatment biopsy identify candidates for surgery, particularly for simple hysterectomy. (2) Surgical Approach: Minimally invasive surgery is not recommended, except for T1A, LVSI-negative tumors, due to a reduction in life expectancy. (3) Locally Advanced Cancer: concurrent chemoradiation (CCRT) followed by brachytherapy (BRT) is the cornerstone treatment. Low-risk patients (fewer than two metastatic nodes or FIGO IB2-II) may consider induction chemotherapy (ICT) followed by CCRT and BRT after 7 days. High-risk patients (two or more metastatic nodes or FIGO IIIA, IIIB, and IVA) benefit from pembrolizumab with CCRT and maintenance therapy. (4) Metastatic, Persistent, and Recurrent Cancer: A PD-L1 status from pretreatment biopsy identifies candidates for Pembrolizumab with available systemic treatment, while triplet therapy (Atezolizumab/Bevacizumab/chemotherapy) becomes a PD-L1-independent option.
: These evidence-based guidelines aim to improve clinical outcomes through precise treatment strategies based on individual risk factors, predictors, and disease stages.</description><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Cellular biology</subject><subject>Cervical cancer</subject><subject>Classification</subject><subject>Clinical trials</subject><subject>Confidence intervals</subject><subject>Cost control</subject><subject>Diagnosis</subject><subject>Evaluation</subject><subject>Evidence-based medicine</subject><subject>Exhumation</subject><subject>Gynecology</subject><subject>Health technology assessment</subject><subject>Human papillomavirus</subject><subject>Immunotherapy</subject><subject>Infections</subject><subject>Medical screening</subject><subject>Minimally invasive surgery</subject><subject>Oncology</subject><subject>Patients</subject><subject>Practice guidelines (Medicine)</subject><subject>Radiotherapy</subject><subject>Risk factors</subject><subject>Womens health</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptkc1rGzEQxUVpaEKSU-9F0ItLsKPPXe3RuIlbCCRQ97zI0siR2ZVSaTfg_z67sVPcktFhBvF7bwYeQp8pmXFekeutaSmnUnBJP6AzRspySrjiH4_mU3SZ85YMpZRgtPyETnlFmSgYOUPd6hHwQ2x8fsS_ovHQ7XB0eLkLYGITN97oBt-H13mHl7230PgAGbuYcDdov3u9CTH7jHWweJVAdy2EbjRZQHp-1S90MJDw5JkRJmbk2wU6cbrJcHno5-j37c1q8WN6d7_8uZjfTQ0nVTd1VhdGWOUsk2WhONXSFs46JikUSqxtZblilipt6FoSzhyjnFthpCTAmeLnaLL3fUrxTw-5q1ufDTSNDhD7XA9bKFNSlGJAv_6HbmOfwnDdSJGKlaw6oja6gdoHF7ukzWhazxURktKKjNTsHWp4FlpvYgDnh_9_BFd7gUkx5wSufkq-1WlXU1KPMddHMQ_0l8Op_boF-5d9C5W_AKqUnqc</recordid><startdate>20240801</startdate><enddate>20240801</enddate><creator>Sznurkowski, Jacek J</creator><creator>Bodnar, Lubomir</creator><creator>Szylberg, Łukasz</creator><creator>Zołciak-Siwinska, Agnieszka</creator><creator>Dańska-Bidzińska, Anna</creator><creator>Klasa-Mazurkiewicz, Dagmara</creator><creator>Rychlik, Agnieszka</creator><creator>Kowalik, Artur</creator><creator>Streb, Joanna</creator><creator>Bidziński, Mariusz</creator><creator>Sawicki, Włodzimierz</creator><general>MDPI AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1349-5906</orcidid><orcidid>https://orcid.org/0000-0003-4767-6369</orcidid><orcidid>https://orcid.org/0000-0001-9218-0245</orcidid><orcidid>https://orcid.org/0000-0002-3718-999X</orcidid><orcidid>https://orcid.org/0000-0003-0122-9504</orcidid></search><sort><creationdate>20240801</creationdate><title>The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Cervical Cancer (v2024.0)</title><author>Sznurkowski, Jacek J ; Bodnar, Lubomir ; Szylberg, Łukasz ; Zołciak-Siwinska, Agnieszka ; Dańska-Bidzińska, Anna ; Klasa-Mazurkiewicz, Dagmara ; Rychlik, Agnieszka ; Kowalik, Artur ; Streb, Joanna ; Bidziński, Mariusz ; Sawicki, Włodzimierz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c309t-fda6c4d8fd2576831a5d6fdf251e684bd9d382d18ac1b5032f2133d4c550e3283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Cellular biology</topic><topic>Cervical cancer</topic><topic>Classification</topic><topic>Clinical trials</topic><topic>Confidence intervals</topic><topic>Cost control</topic><topic>Diagnosis</topic><topic>Evaluation</topic><topic>Evidence-based medicine</topic><topic>Exhumation</topic><topic>Gynecology</topic><topic>Health technology assessment</topic><topic>Human papillomavirus</topic><topic>Immunotherapy</topic><topic>Infections</topic><topic>Medical screening</topic><topic>Minimally invasive surgery</topic><topic>Oncology</topic><topic>Patients</topic><topic>Practice guidelines (Medicine)</topic><topic>Radiotherapy</topic><topic>Risk factors</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sznurkowski, Jacek J</creatorcontrib><creatorcontrib>Bodnar, Lubomir</creatorcontrib><creatorcontrib>Szylberg, Łukasz</creatorcontrib><creatorcontrib>Zołciak-Siwinska, Agnieszka</creatorcontrib><creatorcontrib>Dańska-Bidzińska, Anna</creatorcontrib><creatorcontrib>Klasa-Mazurkiewicz, Dagmara</creatorcontrib><creatorcontrib>Rychlik, Agnieszka</creatorcontrib><creatorcontrib>Kowalik, Artur</creatorcontrib><creatorcontrib>Streb, Joanna</creatorcontrib><creatorcontrib>Bidziński, Mariusz</creatorcontrib><creatorcontrib>Sawicki, Włodzimierz</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sznurkowski, Jacek J</au><au>Bodnar, Lubomir</au><au>Szylberg, Łukasz</au><au>Zołciak-Siwinska, Agnieszka</au><au>Dańska-Bidzińska, Anna</au><au>Klasa-Mazurkiewicz, Dagmara</au><au>Rychlik, Agnieszka</au><au>Kowalik, Artur</au><au>Streb, Joanna</au><au>Bidziński, Mariusz</au><au>Sawicki, Włodzimierz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Cervical Cancer (v2024.0)</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2024-08-01</date><risdate>2024</risdate><volume>13</volume><issue>15</issue><spage>4351</spage><pages>4351-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>: Recent publications underscore the need for updated recommendations addressing less radical surgery for <2 cm tumors, induction chemotherapy, or immunotherapy for locally advanced stages of cervical cancer, as well as for the systemic therapy for recurrent or metastatic cervical cancer.
: To summarize the current evidence for the diagnosis, treatment, and follow-up of cervical cancer and provide evidence-based clinical practice recommendations.
: Developed according to AGREE II standards, the guidelines classify scientific evidence based on the Agency for Health Technology Assessment and Tariff System criteria. Recommendations are graded by evidence strength and consensus level from the development group.
: (1) Early-Stage Cancer: Stromal invasion and lymphovascular space involvement (LVSI) from pretreatment biopsy identify candidates for surgery, particularly for simple hysterectomy. (2) Surgical Approach: Minimally invasive surgery is not recommended, except for T1A, LVSI-negative tumors, due to a reduction in life expectancy. (3) Locally Advanced Cancer: concurrent chemoradiation (CCRT) followed by brachytherapy (BRT) is the cornerstone treatment. Low-risk patients (fewer than two metastatic nodes or FIGO IB2-II) may consider induction chemotherapy (ICT) followed by CCRT and BRT after 7 days. High-risk patients (two or more metastatic nodes or FIGO IIIA, IIIB, and IVA) benefit from pembrolizumab with CCRT and maintenance therapy. (4) Metastatic, Persistent, and Recurrent Cancer: A PD-L1 status from pretreatment biopsy identifies candidates for Pembrolizumab with available systemic treatment, while triplet therapy (Atezolizumab/Bevacizumab/chemotherapy) becomes a PD-L1-independent option.
: These evidence-based guidelines aim to improve clinical outcomes through precise treatment strategies based on individual risk factors, predictors, and disease stages.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39124620</pmid><doi>10.3390/jcm13154351</doi><orcidid>https://orcid.org/0000-0003-1349-5906</orcidid><orcidid>https://orcid.org/0000-0003-4767-6369</orcidid><orcidid>https://orcid.org/0000-0001-9218-0245</orcidid><orcidid>https://orcid.org/0000-0002-3718-999X</orcidid><orcidid>https://orcid.org/0000-0003-0122-9504</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2077-0383 |
| ispartof | Journal of clinical medicine, 2024-08, Vol.13 (15), p.4351 |
| issn | 2077-0383 2077-0383 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3091285474 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Cancer Cancer therapies Care and treatment Cellular biology Cervical cancer Classification Clinical trials Confidence intervals Cost control Diagnosis Evaluation Evidence-based medicine Exhumation Gynecology Health technology assessment Human papillomavirus Immunotherapy Infections Medical screening Minimally invasive surgery Oncology Patients Practice guidelines (Medicine) Radiotherapy Risk factors Womens health |
| title | The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Cervical Cancer (v2024.0) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T19%3A44%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Polish%20Society%20of%20Gynecological%20Oncology%20Guidelines%20for%20the%20Diagnosis%20and%20Treatment%20of%20Cervical%20Cancer%20(v2024.0)&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Sznurkowski,%20Jacek%20J&rft.date=2024-08-01&rft.volume=13&rft.issue=15&rft.spage=4351&rft.pages=4351-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm13154351&rft_dat=%3Cgale_proqu%3EA804511904%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3090927294&rft_id=info:pmid/39124620&rft_galeid=A804511904&rfr_iscdi=true |